WO2001090139A3 - A ligand for enhancing oral and cns delivery of biological agents - Google Patents

A ligand for enhancing oral and cns delivery of biological agents Download PDF

Info

Publication number
WO2001090139A3
WO2001090139A3 PCT/IB2001/000926 IB0100926W WO0190139A3 WO 2001090139 A3 WO2001090139 A3 WO 2001090139A3 IB 0100926 W IB0100926 W IB 0100926W WO 0190139 A3 WO0190139 A3 WO 0190139A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
biological agents
cns delivery
enhancing oral
increases
Prior art date
Application number
PCT/IB2001/000926
Other languages
French (fr)
Other versions
WO2001090139A2 (en
Inventor
Lioudmila Tchistiakova
Shengmin Li
Grzegorz Pietrzynski
Valery Alakhov
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Priority to AU2001260526A priority Critical patent/AU2001260526A1/en
Priority to EP01934229A priority patent/EP1385873A2/en
Priority to JP2001586326A priority patent/JP2004514410A/en
Priority to PCT/IB2001/000926 priority patent/WO2001090139A2/en
Priority to CA002408387A priority patent/CA2408387A1/en
Publication of WO2001090139A2 publication Critical patent/WO2001090139A2/en
Publication of WO2001090139A3 publication Critical patent/WO2001090139A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Provided herein is a novel and useful Ligand comprising a peptide comprising an amino acid sequence of SEQ. ID. NO.:6, an analog, a derivative, or a variant thereof, which increases the absorption of biological agents across the blood brain barrier and the gastrointestinal barrier. As a result, a Ligand of the present invention increases the bioavailability of biological agents administered orally.
PCT/IB2001/000926 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents WO2001090139A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001260526A AU2001260526A1 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents
EP01934229A EP1385873A2 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents
JP2001586326A JP2004514410A (en) 2001-05-07 2001-05-07 Ligands for enhancing oral and CNS supply of biological agents
PCT/IB2001/000926 WO2001090139A2 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents
CA002408387A CA2408387A1 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2001/000926 WO2001090139A2 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents

Publications (2)

Publication Number Publication Date
WO2001090139A2 WO2001090139A2 (en) 2001-11-29
WO2001090139A3 true WO2001090139A3 (en) 2002-06-20

Family

ID=11004110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000926 WO2001090139A2 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents

Country Status (5)

Country Link
EP (1) EP1385873A2 (en)
JP (1) JP2004514410A (en)
AU (1) AU2001260526A1 (en)
CA (1) CA2408387A1 (en)
WO (1) WO2001090139A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
FR2830016B1 (en) * 2001-09-27 2004-06-25 Synt Em COMPOSITIONS FOR THE VECTORIZATION OF TAXOID DERIVATIVES THROUGH THE HEMATOENCEPHALIC BARRIER AND THEIR USE FOR THE TREATMENT OF CANCERS, PARTICULARLY BRAIN CANCERS
PL1877099T3 (en) 2005-04-06 2013-02-28 Genzyme Corp Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
SI2457919T1 (en) 2007-01-18 2019-10-30 Genzyme Corp Oligosaccharides comprising an aminooxy group and conjugates thereof
LT2889043T (en) 2008-12-16 2019-07-10 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599303A2 (en) * 1992-11-27 1994-06-01 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1998056938A1 (en) * 1997-06-13 1998-12-17 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
WO1999022756A1 (en) * 1997-11-04 1999-05-14 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599303A2 (en) * 1992-11-27 1994-06-01 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1998056938A1 (en) * 1997-06-13 1998-12-17 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
WO1999022756A1 (en) * 1997-11-04 1999-05-14 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARDRIDGE W M ET AL: "CHIMERIC PEPTIDES AS A VEHICLE FOR PEPTIDE PHARMACEUTICAL DELIVERY THROUGH THE BLOOD-BRAIN BARRIER", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 146, no. 1, 15 July 1987 (1987-07-15), pages 307 - 313, XP002046937, ISSN: 0006-291X *
See also references of EP1385873A2 *
TAYLOR, EVE M. ET AL.: "DESIGNING STABLE BLOOD-BRAIN BARRIER -PERMEABLE PROSAPTIDE PEPTIDES FOR TREATMENT OF CENTRAL NERVOUS SYSTEM NEURODEGENERATION", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2000) 293(2) 403-409, XP002192428 *

Also Published As

Publication number Publication date
EP1385873A2 (en) 2004-02-04
JP2004514410A (en) 2004-05-20
AU2001260526A1 (en) 2001-12-03
WO2001090139A2 (en) 2001-11-29
CA2408387A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
EA200501744A1 (en) PEPTIDE (VARIANTS), CONTAINING HIS COMPOSITION AND MEDICINAL PREPARATION FOR THE PREVENTION AND TREATMENT OF ASTEROSCLEROSIS
HK1070078A1 (en) Wt1 modified peptide
CY1107146T1 (en) METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE (AD)
WO2002062377A3 (en) Combined use of factor vii polypeptides and factor viii polypeptides
CA2445276A1 (en) Aripiprazole oral solution
PL368408A1 (en) Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
WO1999059609A3 (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
AU6898201A (en) Rgd (arg-gly-asp) coupled to (neuro)peptides
WO2003070755A3 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
BR0214363A (en) Antibody, use of an antibody, drug, method of manufacture of a drug and pharmaceutical package for the treatment of infection.
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
WO2001058470A3 (en) Methods for enhancing the bioavailability of a drug
DE60231649D1 (en) MEANS FOR THE TREATMENT OF EYE ACIDITY AND ASSOCIATED DISEASES
WO2003026700A3 (en) Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
CA2334520A1 (en) Treatment of immune diseases
WO2001068676A3 (en) Lhrh-antagonists, production and use thereof as medicament
WO2000058466A3 (en) Protease resistant flint analogs
EP1790655A3 (en) Biologically active peptides
ATE353669T1 (en) ALLERGY VACCINES AND THEIR PRODUCTION
WO2002050100A3 (en) Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery
EA200300900A1 (en) Substituted amino (OPTIONS), PROCESS FOR THEIR PREPARATION AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS (VARIANTS) COMPOSITION (VARIANTS) INTERMEDIATE iodide AND METHOD OF PREPARATION, METHOD OF TREATMENT PATIENT (VARIANTS)
WO2003022300A1 (en) Preventives/remedies for bone/joint diseases
AU2003202489A1 (en) Screening method
WO2003029290A1 (en) Drug transporter and use thereof
WO2003070770A3 (en) Engineered human kunitz-type protease inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2408387

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 586326

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001934229

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001934229

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001934229

Country of ref document: EP